In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Adding to recent regulatory approvals in the USA and European Union, pharma giant Pfizer can now add the UK to the geographies where its alopecia treatment can be marketed. 1 November 2023
Biosimilars
The US Food and Drug Administration (FDA) yesterday announced it has approved US biotech major Amgen’s Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases. 1 November 2023
Biotechnology
On Tuesday, US biotech company Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, announced a timely update with its Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted). 1 November 2023
Biotechnology
US biotech giant Amgen saw its shares fall by 4.4% to $251.44 on Tuesday, after it announced financial results for the third quarter of 2023. 1 November 2023
Biotechnology
Swiss pharma major Novartis has secured another approval from the US regulator for Cosentyx (secukinumab), a biologic which blocks the IL-17A cytokine. 1 November 2023
Biotechnology
UK clinical-stage biotech STORM Therapeutics, which is targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has appointed Marguerite Hutchinson as its chief business officer. 1 November 2023
Biotechnology
California, USA-based chimeric antigen receptor (CAR) T-cell therapies developer ImmPACT Bio has appointed Han Lee as president and chief financial officer (CFO). 1 November 2023
Biotechnology
An updated version of the coronavirus vaccine developed by Novavax has been approved in Europe, after a positive scientific opinion. 1 November 2023
Biotechnology
UK biotech Fixed Phage has announced that it will change its name to NexaBiome. 31 October 2023
Biotechnology
Danish biotech company Evaxion has announced initial results from a Phase II trial of the first five metastatic melanoma patients treated with EVX-01, a peptide-based personalized cancer vaccine. 31 October 2023
Pharmaceutical
UK pharma major GSK and Arrowhead Pharmaceuticals today announced an agreement for GSK to obtain an exclusive license for JNJ-3989 (formerly ARO-HBV) for treatment of chronic hepatitis B. 31 October 2023
Pharmaceutical
US pharma giant Pfizer was trading more than 1% lower during Tuesday morning’s trading in New York, following the release of financial results. 31 October 2023
Biotechnology
US biotech Beam Therapeutics today announced that Eli Lilly has agreed to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics. 31 October 2023
Biotechnology
UK drugmaker GSK has announced positive headline results from a planned analysis of part one of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III trial. 31 October 2023
Biotechnology
In line with a provisional report issued in September, Boston, USA-based pricing watchdog the Institute for Clinical and Economic Review (ICER) has confirmed guidance on the cost-effectiveness of a new gene therapy. 31 October 2023
Biotechnology
Belgian biotech Galapagos has agreed to sell its Jyseleca (filgotinib) business to Italian drugmaker Alfasigma. 31 October 2023
Pharmaceutical
Shares Japanese drugmaker Sosei Heptares rose 4% to 1,390 yen today, after it announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the approval of daridorexant (ACT-541468). 31 October 2023
Biotechnology
Gilead Sciences Kite unit has agreed a collaboration and research deal with Epicrispr Biotechnologies (Epic Bio), using the latter’s proprietary gene regulation platform to develop next-generation cancer cell therapies. 31 October 2023
Biosimilars
Indian pharmaceutical companies are demonstrating a growing commitment to advancing cancer treatment through substantial investments in biologics. 31 October 2023
Biotechnology
US biotech Sarepta Therapeutics unveiled mixed results late Monday for its gene therapy Elevidys (delandistrogene moxeparvovec-rokl) in patients with Duchenne muscular dystrophy between the ages of four through seven years. The stock was halted in late trading. 31 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze